Table 2.

Baseline characteristics of the patients recruited for the study. Data are expressed as mean ± standard deviation (SD) or percentages (%). Statistical differences between groups of patients were calculated by one-way ANOVA (p < 0.05 was considered significantly).

Discovery phase	Control (n = 10)	CV risk factor (n = 8)	CV event (n = 8)	P-value
Age (years)	44 ± 5	44 ± 6	46 ± 4	0.700
Sex (male), %	60	50	50	0.884
Current smoking, %	0	25	50	0.043
Total cholesterol (mg/dl)	187 ± 25	206 ± 39	145 ± 40	0.008
HDL cholesterol (mg/dl)	72 ± 18	53 ± 13	44 ± 10	0.001
LDL cholesterol (mg/dl)	101 ± 24	131 ± 36	77 ± 32	0.010
Triglycerides (mg/dl)	73 ± 26	139 ± 130	124 ± 67	0.222
Glycaemia (mg/dl)	76 ± 7	104 ± 48	94 ± 30	0.280
Uric acid (mg/dl)	4.8 ± 1.6	5 ± 1	5.5 ± 1.6	0.620
Metabolic syndrome, %	0	25	38	0.171
eGFR (ml/min/1.73 m2)	91 ± 9	97 ± 22	103 ± 34	0.585
Systolic blood pressure (mmHg)	113 ± 10	131 ± 5	125 ± 19	0.017
Diastolic blood pressure (mmHg)	72 ± 8	84 ± 10	78 ± 9	0.034
Antihypertensives, %	0	25	13	0.354
Lipid-lowering agents, %	0	13	13	0.622
QRISK	22 ± 5	33 ± 9	27 ± 6	0.004
Confirmation phase	Control (n = 14)	CV risk factor (n = 15)	CV event (n = 16)	P-value
Age (years)	42 ± 5	45 ± 5	45 ± 5	0.131
Sex (male), %	21	80	94	6.20E-05
Current smoking, %	21	27	56	0.094
Total cholesterol (mg/dl)	198 ± 47	215 ± 39	145 ± 41	0.0001
HDL cholesterol (mg/dl)	69 ± 18	41 ± 16	39 ± 9	1.18E-06
LDL cholesterol (mg/dl)	109 ± 40	139 ± 34	82 ± 40	6.90E-04
Triglycerides (mg/dl)	92 ± 46	221 ± 80	113 ± 67	5.18E-06
Glycaemia (mg/dl)	80 ± 9	95 ± 22	100 ± 15	3.90E-03
Uric acid (mg/dl)	4.5 ± 1.1	6.7 ± 1.8	5.8 ± 1.7	1.99E-03
Metabolic syndrome, %	0	73	6	1.77E-13
eGFR (ml/min/1.73 m2)	95 ± 12	83 ± 9	94 ± 17	0.032
Systolic blood pressure (mmHg)	112 ± 9	138 ± 14	121 ± 20	1.30E-04
Diastolic blood pressure (mmHg)	70 ± 9	90 ± 9	76 ± 12	1.76E-06
Antihypertensives, %	0	40	44	0.016
Lipid-lowering agents, %	0	27	38	0.042
QRISK	23 ± 9	44 ± 9	36 ± 10	1.38E-06